Background. There are few reports regarding the long-term renal replacement therapy (RRT) outcomes of amyloidosis. Methods. In this retrospective, multi-centre, multicountry registry analysis, all patients with and without amyloidosis who commenced RRT for end-stage renal failure (ESRF) in Australia and New Zealand between 1963 and 2010 were included. Results. Of 58 422 patients who underwent RRT during the study period, 490 (0.8%) had ESRF secondary to amyloidosis. The median survival of amyloidosis patients on dialysis (2.09 years, 95% CI 1.85-2.32 years) was significantly inferior to that of patients with other causes of ESRF (4.45 years, 95% CI 4.39-4.51 years) (log-rank score 242, P < 0.001). The survival of amyloidosis patients receiving peritoneal dialysis (1.9 years, 95% CI 1.58-2.22) was comparable with those receiving haemodialysis (2.17 years, 95% CI 1.89-2.45) (P = 0.18). Fifty-three (13.8%) amyloidosis patients died of amyloidosis complications. Forty-six patients underwent renal transplantation with first graft survival rates of 45% at 5 years and 26% at 10 years. Nine (16.4%) patients experienced amyloidosis recurrence in their allografts, which led to graft failure in six patients. ESRF patients with amyloidosis experienced inferior median first renal allograft survival (4.55 years, 95% CI 1.96-7.15 versus 10.7 years, 95% CI 10.5-11.0, P = 0.001) and transplant patient survival (6.03 years, 95% CI 2.71-9.36 versus 16.8 years, 95% CI 16.4-17.1, P < 0.001) compared with patients with other causes of ESRF. Respective 10-year patient survival rates were 37 and 69%.
Introduction
Amyloidosis refers to a group of disorders in which soluble proteins aggregate and deposit in extracellular tissues as insoluble fibrils, causing progressive multiorgan dysfunction. The kidney is one of the most frequent sites of amyloid deposition in immunoglobulin light chain (AL), amyloid A (AA) and several hereditary forms of amyloidosis [1] [2] [3] . Patients typically present with nephrotic syndrome and develop progressive renal impairment, leading to end-stage renal failure (ESRF) [3] [4] [5] .
Available data on the clinical outcomes of patients with amyloidosis undergoing dialysis are limited and have been reported to be inferior to those of other ESRF dialysis patients [5] [6] [7] [8] [9] . A recent study of 221 dialysisdependent AL amyloidosis patients from the UK observed that the median survival on dialysis was 39.0 months [10] , which was much longer than the previously reported values between 8.5 and 26 months [5, 6, 11, 12] . However, there is no detailed epidemiological data available from a large cohort of amyloidosis patients on chronic dialysis. Furthermore, there is little information on renal transplantation outcomes in amyloidosis patients, with existing reports in this area generating conflicting results either favouring or not favouring transplantation for these individuals [13] [14] [15] [16] [17] [18] . Thus, investigations providing additional evidence with larger numbers of patients and longer follow-up are warranted.
The aim of the present study was to investigate the characteristics, treatments and outcomes of all cases of ESRF due to amyloidosis in the Australia and New Zealand dialysis populations, using data from the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry.
Subjects and methods

Patient population
All patients with ESRF enrolled in the ANZDATA Registry, who commenced renal replacement therapy (RRT) between 15 May 1963 and 31 December 2010, were included in the report. ANZDATA collects data on patients whose ESRF is considered irreversible, rather than representing acute kidney injury. Demographic and clinical data were collected throughout the calendar year by medical and nursing staff in each renal unit and submitted every 6 months to the ANZDATA Registry until 2005 and then annually thereafter.
The analyses in this study were based on patients starting RRT for ESRF whose primary renal disease was reported by their nephrologist to be amyloid disease (ANZDATA Registry primary renal disease code 5). The ANZDATA Registry does not collect information on amyloidosis subtypes. Patients with amyloidosis were compared with the remainder of the cohort with an alternative primary renal diagnosis. Dialysis and transplant eras were determined by the dialysis and transplant com- The primary outcomes were overall patient survival on RRT (censored for renal function recovery, loss of follow-up and end of study), patient survival on dialysis (censored for renal function recovery, loss to follow-up, renal transplantation and end of study), renal transplant patient survival (censored for loss to follow-up and end of study) and renal allograft survival (censored for loss to follow-up and end of study). Recovery of dialysis-independent renal function was considered to have occurred if the treating renal unit had recorded that the patient had recovered renal function and completed dialysis therapy. The onset of recovery was defined as the date of the last dialysis treatment.
Statistical analysis
Results were expressed as frequencies and percentages for categorical variables, mean ± standard deviation for continuous normally distributed variables and median [interquartile range; IQR] for continuous variables that were not normally distributed. ESRF patients with or without amyloidosis were compared using chi-square tests, two-tailed, unpaired ttests or Mann-Whitney tests, depending on the data distribution. The independent predictors of amyloidosis ESRF were assessed by multivariable logistic regression analysis. Time-to-event analyses were conducted using Kaplan-Meier and multivariable Cox proportional hazards survival analyses. The covariates included in the model for the entire cohort were age, gender, racial origin, ESRF cause and dialysis era or transplant era (as well as donor type and time from dialysis commencement to renal transplantation for renal transplant analyses). A supplementary, fully adjusted analysis was also conducted using a contemporary cohort (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) in which data were available on body mass index (BMI), smoking status, history of hypertension, chronic lung disease, cerebrovascular disease, ischaemic heart disease, diabetes mellitus, peripheral vascular disease and late referral. Statistical analysis was performed using SPSS software, version 13.0 (SPSS, Inc., Chicago, IL, USA). All P values were two-sided. P < 0.05 were considered statistically significant.
Results
Patient characteristics
Between 15 May 1963 and 31 December 2010, 58 422 individuals started RRT for ESRF. Of these, 490 (0.8%) had ESRF secondary to amyloidosis. The baseline characteristics of ESRF patients with and without amyloidosis are displayed in Table 1 . Using multivariable logistic regression analysis, amyloidosis was significantly associated with older age and Caucasian racial origin (both P < 0.001) compared with other forms of ESRF (Table 2) . In a supplementary analysis using a more contemporary cohort (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) in which complete data were available on comorbidities (n = 36 884 including 299 patients with amyloidosis), amyloidosis was independently associated with older age (P < 0.001), Caucasian racial origin (P = 0.049), lower odds of hypertension (P < 0.001), diabetes mellitus (P < 0.001), cerebral vascular disease (P = 0.003) and higher odds of chronic lung disease (P = 0.013) ( Table 2 ).
Overall patient survival on RRT
The median survival of amyloidosis patients on RRT (2.08 years, 95% CI 1.83-2.32 years) was significantly inferior to that of patients with other causes of ESRF (6.00 years, 95% CI 5.90-6.10 years) (log-rank score 391, P < 0.001). Respective survival rates in the two groups were 73% versus 88% at 1 year, 53% versus 78% at 2 years and 22% versus 55% at 5 years. Amyloidosis was independently associated with higher mortality on RRT in both the entire cohort with limited variable adjustment (adjusted hazard ratio [HR] 2.00, 95% CI 1.82-2.21, P < 0.001) and fully adjusted supplementary analysis of the contemporary (1996-2010) cohort (HR 2.38, 95% CI 2.03-2.79, P < 0.001). The significant difference in RRT survival between amyloidosis patients and those with other causes of ESRF was constant when stratified by the RRT era. When only patients with amyloidosis were considered, death on RRT was only predicted by older age (HR per decade 1.34, 95% CI 1.22-1.47, P < 0.001 in entire cohort). No significant effect of the RRT era on patient survival was observed (log-rank test, P = 0.21).
Patient survival on dialysis and recovery of renal function
Of 490 amyloidosis patients, three patients received preemptive renal transplantation and a total of 487 ESRF patients with amyloidosis initiated RRT by dialysis. Death occurred in 385 (79%) amyloidosis ESRF dialysis patients and 25 928 (46%) patients with ESRF due to other causes (P < 0.001). The proportion of cardiac deaths in amyloidosis ESRF was comparable with that in other ESRF causes (37 versus 41%, respectively), but death from cardiac failure was significantly more common among people with amyloidosis (8.6 versus 2.2%, P < 0.001, respectively). No differences were seen in other causes of death included dialysis withdrawal (22 versus 24%), infections (15 versus 13%), vascular (9 versus 10%), malignancy (6 versus 6%) and other (11 versus 6%).
A total of 53 (13.8%) amyloidosis ESRF patients were reported as dying directly from amyloidosis complications (e.g. cardiac amyloidosis).
The median survival of amyloidosis patients on dialysis (2.09 years, 95% CI 1.85-2.32 years) was significantly inferior to that of patients with other causes of ESRF (4.45 years, 95% CI 4.39-4.51 years) (P < 0.001) ( Figure 1 ). Respective survival rates in the two groups were 73 versus 88% at 1 year, 51 versus 77% at 2 years and 19 versus 45% at 5 years. Amyloidosis was independently associated with higher mortality during dialysis treatment in both the entire cohort with limited variable adjustment (adjusted hazard ratio [HR] 1.90, 95% CI 1.72-2.1, P < 0.001) and fully adjusted supplementary analysis of the contemporary (1996-2010) cohort (HR 2.13, 95% CI 1.87-2.43, P < 0.001). The significant difference in dialysis survival between amyloidosis patients and patients with other causes was constant when stratified by the RRT era.
When only patients with amyloidosis were considered, death on dialysis was only predicted by older age (HR per decade 1.25, 95% CI 1.13-1.39, P < 0.001 in the entire cohort and HR per decade 1.23, 95% CI 1.07-1.41, P = 0.004 in the contemporary cohort). No significant effect of dialysis era on patient survival was observed (log-rank test, P = 0.68). Survival of amyloidosis patients receiving peritoneal dialysis (1.9 years, 95% CI 1.58-2.22) was comparable with those receiving haemodialysis (2.17 years, 95% CI 1.89-2.45) (P = 0.18).
Recovery of dialysis-independent renal function occurred in 4 (0.8%) amyloidosis patients and 888 (1.5%) ESRF patients with another cause of renal disease (P = 0.20). Of the 4 amyloidosis patients who recovered renal function, no patients returned to RRT.
Renal transplant graft survival and disease recurrence
A total of 46 patients with amyloidosis received 55 renal allografts during the study period (Table 3) , which was significantly lower than that of patients with other causes of ESRF (9.4 versus 33.9%, respectively, P < 0.001). Median first renal allograft survival rates in patients with amyloidosis ESRF (4.55 years, 95% CI 1.96-7.15 years) were significantly lower than in patients with other causes Outcomes of ESRF due to amyloidosisof ESRF (10.7 years, 95% CI 10.5-11.0 years) (log-rank score 10.4, P = 0.001) (Figure 2 ). Respective first graft survival rates were 45 versus 69% at 5 years and 26 versus 52% at 10 years. Using multivariable Cox proportional hazards model analysis, amyloidosis was independently associated with renal allograft failure in the entire cohort (HR 1.51, 95% CI 1.08-2.11, P = 0.015). Nine (16.4%) allografts of nine patients with amyloidosis experienced recurrence of original disease, which was significantly more frequent than that observed in 695 allografts (3%) of 581 patients in other causes of ESRF (P < 0.001). Of the nine patients with amyloidosis disease recurrence, graft failure occurred in six patients within a median period of 7.68 (range 3.1, 24.8) years. Other causes of renal allograft failure in the amyloidosis (n = 22) and non-amyloidosis ESRF groups (n = 7881) were chronic allograft nephropathy (27 versus 48%, respectively), acute rejection (23 versus 19%), hyperacute rejection (0 versus 3%), renal artery thrombosis (0 versus 3%), renal vein thrombosis (5 versus 3%), glomerulonephritis (0 versus 5%), non-compliance (0 versus 2%) and other (18 versus 18%).
Renal transplant patient survival
When first renal allografts were considered, the median survival of amyloidosis transplant patients (6.03 years, 95% CI 2.71-9.36) was significantly worse than that of patients with other causes of ESRF (16.8 years, 95% CI 16.4-17.1) (log-rank score 23.2, P < 0.001) (Figure 3 ). Respective 10-year patient survival rates were 37 and 69%. The causes of death in the amyloidosis (n = 33) and non-amyloidosis groups (n = 8728) were cardiac (12 versus 33%), vascular (15 versus 13%), malignancy (12 versus 16%), infection (30 versus 19%), withdrawal (0 versus 8%), amyloidosis (15 versus 0%) and other (15 versus 11%). Five patients were reported to have died of amyloidosis, three from systemic amyloidosis and two from cardiac amyloid. Using multivariable Cox proportional hazards model analysis in the entire cohort, amyloidosis was significantly associated with higher patient mortality following renal transplantation (HR 1.82, 95% CI 1.28-2.59, P = 0.001). When survival analyses were alternatively censored for renal allograft failure, the median survival of amyloidosis transplant patients (8.28 years, 95% CI 0.32-16.24) remained inferior to that of patients with other causes of ESRF (21.6 years, 95% CI 20.87-22.30) (P = 0.001).
Discussion
In this retrospective, multi-centre, multi-country registry analysis, the outcomes of 490 ESRF patients with amyloidosis were compared with those of 57 932 patients with ESRF due to other causes. Our study found that amyloidosis was associated with worse patient survival on dialysis as well as following renal transplantation, poorer renal allograft survival and a greater propensity to disease recurrence in the graft compared with patients with other forms of primary renal disease. A substantial number of amyloidosis ESRF patients died of amyloidosis complications. There is little information on the outcome of amyloidosis patients on dialysis, although it is generally considered that survival is low [19] . A retrospective study of 48 dialysis patients with systemic amyloidosis reported 1-, 2-and 6-year actuarial survival rates of 72, 62 and 44%, respectively, which were significantly lower than the corresponding rates in non-diabetic controls (95, 91 and 81%, respectively) [20] . The median survival of the amyloidosis group was 52 months. In contrast, Gertz et al. [6] reported a very poor median survival of only 8.2 months in 37 patients with AL amyloidosis undergoing dialysis prior to 1992. Two more recent studies of dialysis patients with both AL and AA amyloidosis (8 and 39 patients, respectively) found that median survival ranged from 10.4 to 26 months [5, 12] . A retrospective, observational cohort study of 96 patients with biopsy-proven amyloidosis in 45 Italian renal units between 1995 and 2000 demonstrated dialysis survival rates in AL (n = 59) and AA (n = 37) amyloidosis of 48 and 75% at 1 year, and 18 and 12% at 5 years [11] . The survival of patients with AL amyloidosis was worse than that of AA amyloidosis primarily due to cardiac involvement, but was significantly improved in those who received specific therapy (such as autologous stem cell transplantation). A report of 221 dialysis-dependent AL amyloidosis patients from the United Kingdom National Amyloidosis Centre (1987-2008) observed a median survival of 39.0 months, although the rate was significantly higher after 2002 (43.6 months) compared with beforehand (29.8 months) [10] . The survival rates of amyloidosis patients in the Italian and UK studies were very similar to those observed in Australia and New Zealand in the current study (median survival 2.09 years, 1 year survival 73%, 5 year survival 19%). The larger sample size and longer follow-up in the present study greatly improved the precision of derived survival estimates. However, the inability to distinguish between patients with AA and AL amyloidosis was a limitation. The present study also found no significant difference in survival between PD and HD amyloidosis patients, suggesting that both modalities should be considered when treating amyloidosis ESRF patients. Although previous studies have shown comparable outcomes in amyloidosis patients according to dialysis modality, their small sample sizes (37-96 patients) limited the strength of the conclusions that could be drawn due to the possibility of a type 2 statistical error [6, 11, 20] .
There have also been limited, conflicting data on renal transplant outcomes in patients with amyloidosis. In a retrospective observational cohort study of 23 amyloidotic transplant recipients, Sheriff et al. [14] observed 10-year patient and graft survival rates of 66 and 68%, respectively, which were not significantly different from 47 non-amyloidotic controls (57 and 87%, respectively). Recurrence of amyloidosis in the renal allograft rate was only 4.3% [14] . In contrast, Pasternack et al. [17] observed that 45 amyloidotic transplant recipients experienced inferior 3-year patient survival (51 versus 79%) and graft survival (38 versus 45%) compared with 45 controls. Amyloidosis recurrence occurred in 9% of renal allografts. Haq et al. [3] similarly demonstrated that 13 ESRF patients with amyloidosis undergoing renal transplantation had significantly worse 5-year patient survival (69 versus 87%) and graft survival (56 versus 59%) compared with 142 patients with other causes of ESRF. Furthermore, a recent multi-centre, retrospective, observational study of renal transplant recipients found that 59 individuals with AA amyloidosis had significantly inferior 10-year patient survival rates compared with controls (61.7 versus 83.4%, respectively), but comparable 10-year death-censored graft survival rates (77.5 versus 71.3%). Recurrence of AA amyloidosis occurred in 14% of renal allografts and was independently predictive of mortality (OR 14.4, 95% CI 1.51-727) [18] . These results are very similar to those of our study of 55 renal allografts in 46 patients with amyloidosis, in which amyloidosis was independently associated with worse patient survival (P < 0.001). The amyloidosis recurrence rate was 16%. However, in contrast to the previous study, graft survival of amyloidosis patients in the present study was significantly worse than that of patients with other causes of ESRF.
In our series, 14% of deaths on dialysis and 15% of deaths following renal transplantation resulted from amyloidosis complications, emphasizing that thorough evaluation of systemic complications remains important even after patients with renal amyloidosis progress to ESRF. Previous studies have similarly demonstrated a high rate of adverse clinical outcomes related to amyloidosis complications, especially cardiovascular involvement leading to heart failure [5, 9, 11, 12] . Specific treatment, such as autologous stem cell transplantation for AL amyloidosis, should therefore be considered to prevent or minimize such organ involvement in amyloidosis ESRF patients.
The strengths of this study include its very large sample size and inclusiveness. We included all patients with ESRF secondary to amyloidosis or other causes in Australia and New Zealand during the study period, such that a variety of centres were included with varying approaches to amyloidosis. This greatly enhanced the external validity of our findings. Nevertheless, our study also had several limitations and biases, the main one being that the ANZDATA Registry coding for amyloidosis as a cause for ESRF does not allow for distinction between subtypes of amyloidosis (AL, AA or other types). Another weakness of this study was the limited depth of data collection. ANZDATA does not collect important information, such as severity of comorbidities, concomitant medications, patient compliance, individual unit management protocols (including amyloidosis-specific treatment protocols) and laboratory values (such as serum free light chain, serum AA and echocardiographic results). Even though we adjusted for a large number of patient characteristics, the possibility of residual confounding could not be excluded. In common with other registries, ANZDATA is a voluntary registry and there is no external audit of data accuracy, including the diagnosis of amyloidosis. Consequently, the possibility of coding/classification bias cannot be excluded. Finally, ascertainment bias may have influenced the results of the study. The comparable cardiac mortality between dialysis patients with and without amyloidosis suggests that cardiac involvement may have been uncommon in the amyloidosis dialysis population, possibly due to patients with cardiac amyloidosis dying prior to the development of ESRF.
In conclusion, amyloidosis was associated with poor patient survival following dialysis and/or renal transplantation, reduced renal allograft survival and a significant incidence of disease recurrence in the allograft. An appreciable proportion of amyloid ESRF patients died of amyloidosis complications. 
